JP2012500389A5 - - Google Patents

Download PDF

Info

Publication number
JP2012500389A5
JP2012500389A5 JP2011523144A JP2011523144A JP2012500389A5 JP 2012500389 A5 JP2012500389 A5 JP 2012500389A5 JP 2011523144 A JP2011523144 A JP 2011523144A JP 2011523144 A JP2011523144 A JP 2011523144A JP 2012500389 A5 JP2012500389 A5 JP 2012500389A5
Authority
JP
Japan
Prior art keywords
mir
gene product
multiple myeloma
marker
mirna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011523144A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012500389A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/053586 external-priority patent/WO2010019694A1/en
Publication of JP2012500389A publication Critical patent/JP2012500389A/ja
Publication of JP2012500389A5 publication Critical patent/JP2012500389A5/ja
Pending legal-status Critical Current

Links

JP2011523144A 2008-08-12 2009-08-12 多発性脊髄腫の診断、予後および治療のためのマイクロｒｎａに基づく組成物および方法 Pending JP2012500389A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8803608P 2008-08-12 2008-08-12
US61/088,036 2008-08-12
PCT/US2009/053586 WO2010019694A1 (en) 2008-08-12 2009-08-12 Micro-rna-based compositions and methods for the diagnosis, prognosis and treatment of multiple myeloma

Publications (2)

Publication Number Publication Date
JP2012500389A JP2012500389A (ja) 2012-01-05
JP2012500389A5 true JP2012500389A5 (enExample) 2012-09-13

Family

ID=41669274

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011523144A Pending JP2012500389A (ja) 2008-08-12 2009-08-12 多発性脊髄腫の診断、予後および治療のためのマイクロｒｎａに基づく組成物および方法

Country Status (7)

Country Link
US (1) US20110152357A1 (enExample)
EP (1) EP2323677A4 (enExample)
JP (1) JP2012500389A (enExample)
CN (1) CN102149401A (enExample)
AU (1) AU2009281969A1 (enExample)
CA (1) CA2734179A1 (enExample)
WO (1) WO2010019694A1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103820562B (zh) 2005-08-01 2015-05-13 俄亥俄州立大学研究基金会 用于乳腺癌的诊断、预后和治疗的基于MicroRNA的方法和组合物
CA2621441C (en) 2005-09-12 2014-05-20 The Ohio State University Research Foundation Compositions and methods for the diagnosis and therapy of bcl2-associated cancers
CN101384273B (zh) 2006-01-05 2013-07-10 俄亥俄州立大学研究基金会 胰腺内分泌和腺泡肿瘤中的微小rna表达异常
EP2484782B1 (en) 2006-01-05 2015-11-18 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers
EP2502630B1 (en) 2006-01-05 2015-03-11 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
EP2369013A1 (en) 2006-03-20 2011-09-28 The Ohio State University Research Foundation Micro-RNA fingerprints during human megakaryocytopoiesis
EP2455493B1 (en) 2006-07-13 2014-01-08 The Ohio State University Research Foundation Micro-RNA-based methods and compositions for the diagnosis and treatment of colon related diseases
CA2663027A1 (en) 2006-09-19 2008-08-14 The Ohio State University Research Foundation Tcl1 expression in chronic lymphocytic leukemia (cll) regulated by mir-29 and mir-181
US8252538B2 (en) 2006-11-01 2012-08-28 The Ohio State University MicroRNA expression signature for predicting survival and metastases in hepatocellular carcinoma
CN103555825B (zh) 2007-01-31 2015-09-30 俄亥俄州立大学研究基金会 用于急性髓细胞白血病(aml)的诊断、预后和治疗的基于微rna的方法和组合物
CN101711287B (zh) 2007-06-08 2016-04-27 由卫生与公众服务部代表的美利坚合众国政府 确定肝细胞癌亚型和检测肝癌干细胞的方法
AU2008266014B2 (en) 2007-06-15 2013-06-06 The Ohio State University Research Foundation Oncogenic ALL-1 fusion proteins for targeting drosha-mediated microRNA processing
CN101809169B (zh) 2007-07-31 2013-07-17 俄亥俄州立大学研究基金会 通过靶向dnmt3a和dnmt3b恢复甲基化的方法
EP2173908B1 (en) 2007-08-03 2016-01-06 The Ohio State University Research Foundation Ultraconserved regions encoding ncrnas
CA2926831A1 (en) 2007-08-22 2009-02-26 The Ohio State University Research Foundation Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias
CA2703707A1 (en) 2007-10-26 2009-04-30 The Ohio State University Research Foundation Methods for identifying fragile histidine triad (fhit) interaction and uses thereof
CA2727633A1 (en) 2008-06-11 2009-12-17 Xin W. Wang Use of mir-26 family as a predictive marker for hepatocellular carcinoma and responsiveness to therapy
EP2504452A4 (en) 2009-11-23 2014-06-11 Univ Ohio State Res Found MATERIALS AND METHODS FOR INFLUENCING GROWTH, MIGRATION AND INVASION OF TUMOR CELLS
CN102241773B (zh) * 2010-05-13 2014-05-14 四川大学 抗骨髓瘤细胞多克隆抗体及其制备方法
CN103648505B (zh) 2010-11-12 2016-09-28 俄亥俄州立大学研究基金会 与微rna-21、错配修复和结肠直肠癌相关的材料和方法
BR112013011942A2 (pt) 2010-11-15 2016-11-01 Univ Michigan formulação, forma de dosagem de droga para administração transmucosa oral, sistema transmucoso de fornecimento de droga, método de tratamento e profilaxia de uma doença ou distúrbio, método de tratamento, formulação, método para tratamento ou prevenção de carcinoma de célula escamosa de cabeça e pescoço (hnscc), método para quimioprevenção de um câncer oral ou condição pré-cancerosa, método para aumentar a concentração de uma composição de retinida, método de tratamento e profilaxia de uma doença ou condição, método de ratamento de um sujeito apresentando uma condição médica sintomática, método de tratamento de um câncer oral ou condição pré-cancerosa num paciente, método para fazer um sistema de fornecimento de droga bucal, método para aumentar a liberação e permeação de uma composição de retinida.
GB2486424A (en) * 2010-12-13 2012-06-20 Univ Sussex Markers for plasma cell disorders
CA2828772A1 (en) 2011-03-07 2012-09-13 The Ohio State University Mutator activity induced by microrna-155 (mir-155) links inflammation and cancer
JP2014511677A (ja) * 2011-03-22 2014-05-19 コーネル・ユニバーシティー 鑑別困難な良性甲状腺病変と悪性甲状腺病変との識別法
US8945829B2 (en) 2011-03-22 2015-02-03 Cornell University Distinguishing benign and malignant indeterminate thyroid lesions
EP2766500A4 (en) 2011-10-14 2015-10-14 Univ Ohio State METHOD AND MATERIALS IN CONNECTION WITH EGG CANCER
CN104254366B (zh) 2011-12-09 2017-03-08 麦特文申公司 用于神经调节的设备、系统和方法
CA2859430A1 (en) 2011-12-13 2013-06-20 Ohio State Innovation Foundation Methods and compositions related to mir-21 and mir-29a, exosome inhibition, and cancer metastasis
US8859202B2 (en) 2012-01-20 2014-10-14 The Ohio State University Breast cancer biomarker signatures for invasiveness and prognosis
JP6581502B2 (ja) 2012-08-20 2019-09-25 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 初期段階の肺がんにおける予後指標としてのタンパク質コーディング遺伝子及び非コーディング遺伝子の発現
WO2014071205A1 (en) * 2012-11-02 2014-05-08 Dana-Farber Cancer Institute, Inc. Compositions and methods for diagnosis, prognosis and treatment of hematological malignancies
CA3007426A1 (en) * 2015-12-03 2017-06-08 Alfred Health Monitoring treatment or progression of myeloma
CN105603087B (zh) * 2016-02-01 2019-03-01 中国医学科学院血液病医院（血液学研究所） 检测多发性骨髓瘤克隆进化的基因探针组合物及试剂盒
EP3481403B1 (en) * 2016-07-06 2022-02-09 Youhealth Biotech, Limited Solid tumor methylation markers and uses thereof
CN110223733B (zh) * 2019-04-22 2022-02-01 福建医科大学附属第一医院 一种多发性骨髓瘤预后基因的筛查方法
AU2020268798A1 (en) 2019-05-03 2021-11-04 Dicerna Pharmaceuticals, Inc. Double-stranded nucleic acid inhibitor molecules with shortened sense strands
US20210002698A1 (en) * 2019-07-02 2021-01-07 Quark Biosciences Taiwan, Inc. miRNA Receptivity Analysis of the Endometrium
CN110564852A (zh) * 2019-08-06 2019-12-13 中国医学科学院血液病医院(中国医学科学院血液学研究所) 与人类多发性骨髓瘤相关的miRNAs表达图谱模型、构建方法及应用
CN113186163A (zh) * 2021-01-18 2021-07-30 南昌五元生物科技有限公司 一种基于p53突变筛选肿瘤类器官的培养方法
US12529106B2 (en) 2023-06-09 2026-01-20 Inti Taiwan, Inc. Assays and methods to assist in vitro fertilization

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2554818A1 (en) * 2004-02-09 2005-08-25 Thomas Jefferson University Diagnosis and treatment of cancers with microrna located in or near cancer-associated chromosomal features
EP2290073A3 (en) * 2004-05-28 2011-08-31 Asuragen, Inc. Methods and compositions involving microRNA
CA2857878A1 (en) * 2004-11-12 2006-12-28 Asuragen, Inc. Methods and compositions involving mirna and mirna inhibitor molecules
US20060185027A1 (en) * 2004-12-23 2006-08-17 David Bartel Systems and methods for identifying miRNA targets and for altering miRNA and target expression
EP1880027B1 (en) * 2005-05-02 2014-02-19 Cold Spring Harbor Laboratory Composition and methods for cancer diagnosis utilizing the mir 17-92 cluster
EP2369013A1 (en) * 2006-03-20 2011-09-28 The Ohio State University Research Foundation Micro-RNA fingerprints during human megakaryocytopoiesis
EP2455493B1 (en) * 2006-07-13 2014-01-08 The Ohio State University Research Foundation Micro-RNA-based methods and compositions for the diagnosis and treatment of colon related diseases
JP2010510964A (ja) * 2006-09-19 2010-04-08 アシュラジェン インコーポレイテッド 治療的介入の標的としての、ｍｉＲ−１５、ｍｉＲ−２６、ｍｉＲ−３１、ｍｉＲ−１４５、ｍｉＲ−１４７、ｍｉＲ−１８８、ｍｉＲ−２１５、ｍｉＲ−２１６、ｍｉＲ−３３１、ｍｍｕ−ｍｉＲ−２９２−３ｐによって調節される遺伝子および経路
ATE553196T1 (de) * 2007-02-27 2012-04-15 Rosetta Genomics Ltd Zusammensetzung und verfahren zur modulation von zellproliferation und zelltod
JP5331714B2 (ja) * 2007-03-16 2013-10-30 コヴァルクス・アーゲー タンパク質複合体をターゲティングする薬物候補の直接質量分析
ES2936256T3 (es) * 2008-02-01 2023-03-15 Massachusetts Gen Hospital Uso de microvesículas en el diagnóstico, y pronóstico de enfermedades y afecciones médicas

Similar Documents

Publication Publication Date Title
JP7186700B2 (ja) 腫瘍抑制ｆｏｘｏ活性を酸化ストレスから区別する方法
JP2009543552A5 (enExample)
JP2011500071A (ja) 遺伝子に基づくアルゴリズム的ガン予後及び患者の臨床結果
CN102618641B (zh) 测量对多西他赛抗药性或敏感性的试剂盒
JP2010535473A5 (enExample)
KR20120065959A (ko) 위암의 예후 예측용 마커 및 이를 이용하는 위암의 예후 예측 방법
JP2011517932A5 (enExample)
JP2010535782A5 (ja) メチルトランスフェラーゼを標的にすることによるメチル化を元に戻す方法
CN109837340B (zh) 用于肺癌无创诊断的外周血基因标记物
WO2013052480A1 (en) Marker-based prognostic risk score in colon cancer
CN103608683A (zh) Hedgehog抑制剂治疗的生物标志物
JP6546248B2 (ja) ｍｉＲＮＡの発現を分析することによって大腸癌の転帰を予測するための方法
JP2008539731A (ja) 癌の診断及び治療のための組成物及び方法
CN109996893A (zh) 鉴定心脏发育基因模式的表观基因组范围相关的研究和一类新的心力衰竭生物标记物
TW201812125A (zh) 使用藥物基因體學標記的組合物及方法
JP2008512984A5 (enExample)
US20120095030A1 (en) Methods and kits to predict therapeutic outcome of tyrosine kinase inhibitors
CN102027131A (zh) 癌症分期与治疗的系统和方法
WO2012130720A2 (en) PREDICTION OF RESPONSIVENESS TO PIK3/mTOR INHIBITORS
Mullen et al. Modeling susceptibility to cardiotoxicity in cancer therapy using human iPSC-derived cardiac cells and systems biology
US20110269636A1 (en) Materials and methods for identifying patients at heighten risk for developing her2+ related brain tumors
Picard et al. Integrative genomic analyses identify LIN28 and OLIG2 as markers of survival and metastatic potential in childhood central nervous system primitive neuro-ectodermal brain tumours
AU2012200305A1 (en) Method for measuring resistance or sensitivity to docetaxel
Naderi Molecular Functions of the Androgen Receptor and BEX2 in Breast Cancer
HK1111441B (en) Method for measuring resistance or sensitivity to docetaxel